Table 1.

Effect of treatment with anti–LFA-1 antibodies (α–LFA-1) and G-CSF on blood cell counts

Treatment
White blood cells,
× 109/L
Neutrophils,
× 109/L
Platelets,
× 109/L
Saline 8.3 ± 1.7 2.0 ± 0.7 1068 ± 279 
Saline    
 G-CSF 2 d, 2.5 μg/d 9.8 ± 2.5 2.8 ± 1.6 738 ± 84 
α–LFA-1    
 G-CSF 2 d, 2.5 μg/d 9.3 ± 1.7 2.6 ± 0.5 309 ± 58* 
Saline    
 G-CSF 1 d, 5 μg/d 13.3 ± 3.5 7.0 ± 2.0 610 ± 367 
α–LFA-1    
 G-CSF 1 d, 5 μg/d 8.2 ± 1.6 3.3 ± 0.4 281 ± 85* 
Saline    
 G-CSF 2 d, 5 μg/d 12.4 ± 3.0 4.6 ± 2.0 936 ± 244 
α–LFA-1    
 G-CSF 2 d, 5 μg/d 8.9 ± 1.6 3.2 ± 1.8 634 ± 111* 
Saline    
 G-CSF 3 d, 5 μg/d 10.5 ± 3.2 3.4 ± 1.1 709 ± 180 
α–LFA-1    
 G-CSF 3 d, 5 μg/d 8.4 ± 1.8 3.6 ± 1.1 351 ± 313* 
Saline    
 G-CSF 5 d, 5 μg/d 19.6 ± 2.8 12.5 ± 2.3 705 ± 89 
α–LFA-1    
 G-CSF 5 d, 5 μg/d 22.8 ± 6.3 16.3 ± 4.1 922 ± 313 
Treatment
White blood cells,
× 109/L
Neutrophils,
× 109/L
Platelets,
× 109/L
Saline 8.3 ± 1.7 2.0 ± 0.7 1068 ± 279 
Saline    
 G-CSF 2 d, 2.5 μg/d 9.8 ± 2.5 2.8 ± 1.6 738 ± 84 
α–LFA-1    
 G-CSF 2 d, 2.5 μg/d 9.3 ± 1.7 2.6 ± 0.5 309 ± 58* 
Saline    
 G-CSF 1 d, 5 μg/d 13.3 ± 3.5 7.0 ± 2.0 610 ± 367 
α–LFA-1    
 G-CSF 1 d, 5 μg/d 8.2 ± 1.6 3.3 ± 0.4 281 ± 85* 
Saline    
 G-CSF 2 d, 5 μg/d 12.4 ± 3.0 4.6 ± 2.0 936 ± 244 
α–LFA-1    
 G-CSF 2 d, 5 μg/d 8.9 ± 1.6 3.2 ± 1.8 634 ± 111* 
Saline    
 G-CSF 3 d, 5 μg/d 10.5 ± 3.2 3.4 ± 1.1 709 ± 180 
α–LFA-1    
 G-CSF 3 d, 5 μg/d 8.4 ± 1.8 3.6 ± 1.1 351 ± 313* 
Saline    
 G-CSF 5 d, 5 μg/d 19.6 ± 2.8 12.5 ± 2.3 705 ± 89 
α–LFA-1    
 G-CSF 5 d, 5 μg/d 22.8 ± 6.3 16.3 ± 4.1 922 ± 313 

On day 0, mice were treated with a single intraperitoneal injection of 100 μg antibody or saline. Twenty-four hours later, G-CSF was administered as a once-daily injection. Twenty-four hours after the last injection of G-CSF, mice were killed and blood was obtained by a cardiac puncture. Results are expressed as mean ± SD (n = 3-18, 2-3 experiments).

*

P < .05 compared with the saline-pretreated controls.

or Create an Account

Close Modal
Close Modal